Low-dose naltrexone plays antineoplastic role in cervical cancer progression through suppressing PI3K/AKT/mTOR pathway

被引：11

作者：

Liu, Ning ^{[1
]}

Yan, Limei ^{[1
]}

Shan, Fengping ^{[2
]}

Wang, Xiaonai ^{[2
]}

Qu, Na ^{[3
]}

Handley, Mike K. ^{[4
]}

Ma, Mingxing ^{[5
]}

机构：

[1] China Med Univ, Shengjing Hosp, Dept Obstet & Gynecol, 36 Sanhao St, Shenyang 110004, Liaoning, Peoples R China

[2] China Med Univ, Dept Immunol, Coll Basic Med Sci, Shenyang North New Area, 77 Puhe Rd, Shenyang 110122, Liaoning, Peoples R China

[3] China Med Univ, Liaoning Canc Hosp & Inst, Canc Hosp, Dept Gynecol, 44 Xiaoheyan Rd, Shenyang 110042, Liaoning, Peoples R China

[4] Cytocom Inc, 37 North Orange Ave,Suite 607, Orlando, FL 32801 USA

[5] China Med Univ, Shengjing Hosp, Dept Gen Surg, 36 Sanhao St, Shenyang 110004, Liaoning, Peoples R China

来源：

TRANSLATIONAL ONCOLOGY | 2021年 / 14卷 / 04期

关键词：

Low-dose naltrexone; Cervical cancer; Proliferation; Invasion; PI3K; AKT; mTOR; EPITHELIAL-MESENCHYMAL TRANSITION; METASTASIS; SNAIL2; LDN;

D O I：

10.1016/j.tranon.2021.101028

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The incidence of cervical cancer is increasing annually worldwide. Low-dose naltrexone (LDN) has been reported to delay tumor progression, but the mechanism remains unclear. Here, we found that low-dose naltrexone could upregulate the expression of OGFr. Additionally, LDN could suppress the abilities of colony formation, migration and invasion in cervical cancer cells. LDN could also inhibit cervical cancer progression in mice model. Moreover, LDN indirectly reduced the expressions of PI3K, pAKT and mTOR in vitro and in vivo. Therefore, LDN may be considered a potential treatment option for cervical cancer.

引用

页数：8

共 50 条

[41] Prospects of targeting PI3K/AKT/mTOR pathway in pancreatic cancer
Mortazavi, Motahareh
Moosavi, Fatemeh
Martini, Miriam
Giovannetti, Elisa
Firuzi, Omidreza
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2022, 176
[42] Targeting the PI3K/Akt/mTOR Pathway for Breast Cancer Therapy
Cidado, Justin
Park, Ben Ho
JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA, 2012, 17 (3-4) : 205 - 216
[43] Targeting the PI3K/Akt/mTOR pathway for cancer prevention.
Dennis, PA
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2005, 14 (11) : 2800S - 2801S
[44] The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer
Mabuchi, Seiji
Kuroda, Hiromasa
Takahashi, Ryoko
Sasano, Tomoyuki
GYNECOLOGIC ONCOLOGY, 2015, 137 (01) : 173 - 179
[45] Targeting the PI3K/Akt/mTOR Pathway for Breast Cancer Therapy
Justin Cidado
Ben Ho Park
Journal of Mammary Gland Biology and Neoplasia, 2012, 17 : 205 - 216
[46] Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway
Polivka, Jiri, Jr.
Janku, Filip
PHARMACOLOGY & THERAPEUTICS, 2014, 142 (02) : 164 - 175
[47] PI3K/Akt/mTOR signaling pathway in cancer stem cells
Fath, Mohsen Karami
Ebrahimi, Menooa
Nourbakhsh, Ehsan
Hazara, Ahmad Zia
Mirzaei, Ali
Shafieyari, Saba
Salehi, Azadeh
Hoseinzadeh, Mahsa
Payandeh, Zahra
Barati, Ghasem
PATHOLOGY RESEARCH AND PRACTICE, 2022, 237
[48] Gambogic acid affects ESCC progression through regulation of PI3K/AKT/mTOR signal pathway
Yu, Jiarui
Wang, Wei
Yao, Weinan
Yang, Zhao
Gao, Peng
Liu, Meiyue
Wang, Huan
Chen, Siyuan
Wang, Dan
Wang, Weixi
Sun, Guogui
JOURNAL OF CANCER, 2020, 11 (19): : 5568 - 5577
[49] TRAM2 promotes the malignant progression of glioma through PI3K/AKT/mTOR pathway
Gao, Xiang
Jiang, Wenqu
Ke, Zunliang
Huang, Qiwei
Chen, Liang
Zhang, Guobin
Li, Chao
Yu, Xiaojun
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2022, 586 : 34 - 41
[50] COPS8 promotes hepatocellular carcinoma progression through the PI3K/AKT/mTOR pathway
Yan, Xiaodong
Li, Zhongmin
Tian, Qing
Zhang, Yamin
ASIAN JOURNAL OF SURGERY, 2024, 47 (06) : 2947 - 2949

← 1 2 3 4 5 →